drugset
drugset / Trial / NCT00336024

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

NCT00336024 ↗

Phase 3 Completed 91 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma when given before additional intense chemotherapy followed by peripheral blood stem cell rescue. It is not yet known which combination chemotherapy regimen is more effective when given before a peripheral stem cell transplant in treating supratentorial primitive neuroectodermal tumors or medulloblastoma.

Timeline

Start
2007-10-22
Primary completion
2016-12-31
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule — Intravenous
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous
Background Etoposide Small molecule — Intravenous
Background Leucovorin Small molecule — Intravenous
Background Thiotepa Other / unclassified — Intravenous
Background Vincristine Small molecule — Intravenous
Background filgrastim Protein / enzyme biologic — Intravenous

Indications

anaplastic/large cell medulloblastoma supratentorial primitive neuroectodermal tumor